TLR9: A Double-Dealing Toll-Like Receptor.

In 2011, the Nobel Prize was awarded for the discovery of Toll-like receptors (TLRs) and their critical role in immunity. TLR9 is a key pattern recognition receptor that detects unmethylated cytosine-phosphate-guanine (CpG) DNA motifs, triggering innate and adaptive immune responses against pathogens and damaged host cells. Upon activation, TLR9 triggers signaling cascades that drive NF-κB, STAT3, and MAPK pathways, modulating inflammatory responses, cellular survival mechanisms, and immune regulation. While TLR9 activation is essential for immune defense, TLR9 acts as a double-dealing TLR in multiple pathologies, including cancer, autoimmunity, and chronic inflammatory disease. In cancer biology, TLR9 exhibits context-dependent roles, acting as a driver of tumorigenesis, a suppressor of tumor growth, and a regulator of immune responses, depending on the tumor type, signaling pathway, and microenvironment. It promotes tumorigenesis in leukemias, gliomas, and cancers of the prostate, bone, lung, and gastrointestinal tract, yet displays tumor-suppressive effects in triple-negative breast cancer, renal cell carcinoma, and virally-associated malignancies, through a variety of mechanisms. Clinically, synthetic CpG oligodeoxynucleotides (ODNs), which function as TLR9 agonists, have emerged as a promising approach in cancer immunotherapy, particularly in combination with other potent anticancer therapies. However, the dual nature of TLR9 signaling poses challenges for therapeutic applications. Its context-dependent effects contribute to inconsistent clinical outcomes and raise concerns about safety and toxicity. This review examines the immunologic function and signaling mechanisms of TLR9, with a focus on its complex, context-specific, and "double-dealing" roles in cancer pathogenesis and therapy.